Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer, Phase III study finds
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival (EFS) in patients with resectable early-stage non-small ...
May 15, 2024
0
52